Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial

R Sundar, NB Kumarakulasinghe, YH Chan, K Yoshida… - Gut, 2022 - gut.bmj.com
Objective To date, there are no predictive biomarkers to guide selection of patients with
gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional …
被引用次数：41 相关文章
[PDF] bmj.com

[PDF][PDF] Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial

R Sundar, NB Kumarakulasinghe, YH Chan, K Yoshida… - Gut, 2021 - gut.bmj.com
Objective To date, there are no predictive biomarkers to guide selection of patients with
gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional …

Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial.

R Sundar, K Yoshida, T Yoshikawa, Y Miyagi, Y Rino… - Gut, 2021 - europepmc.org
Objective To date, there are no predictive biomarkers to guide selection of patients with
gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional …

Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: Results from the randomised phase III SAMIT trial

R Sundar, KN Barr, CY Huak, K Yoshida, T Yoshikawa… - Gut, 2022 - scholarworks.bwise.kr
Objective: To date, there are no predictive biomarkers to guide selection of patients with
gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional …
[HTML] nih.gov

[HTML][HTML] Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial

R Sundar, NB Kumarakulasinghe, YH Chan, K Yoshida… - Gut, 2022 - ncbi.nlm.nih.gov
Objective To date, there are no predictive biomarkers to guide selection of patients with
gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional …

Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial

R Sundar, NB Kumarakulasinghe, YH Chan, K Yoshida… - Gut, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Objective</jats: title>< jats: p> To date, there are no predictive
biomarkers to guide selection of patients with gastric cancer (GC) who benefit from …

Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial

R Sundar, NB Kumarakulasinghe, YH Chan, K Yoshida… - Gut, 2022 - search.proquest.com
Objective To date, there are no predictive biomarkers to guide selection of patients with
gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional …

Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial

R Sundar, NB Kumarakulasinghe, YH Chan… - Gut, 2022 - pubmed.ncbi.nlm.nih.gov
Objective To date, there are no predictive biomarkers to guide selection of patients with
gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional …
[PDF] mumc.nl

[PDF][PDF] Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial

R Sundar, NB Kumarakulasinghe, YH Chan, K Yoshida… - pathologie.mumc.nl
Objective To date, there are no predictive biomarkers to guide selection of patients with
gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional …

Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial

R Sundar, NB Kumarakulasinghe, YH Chan… - Gut, 2022 - cris.maastrichtuniversity.nl
Objective To date, there are no predictive biomarkers to guide selection of patients with
gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional …